Goldar (Tibolone)

Goldar is prescribed for the relief of menopausal symptoms and for the treatment of estrogen deficiency in post‑menopausal women, helping to restore hormonal balance.

• Reduction of hot flashes and night sweats, providing more comfortable temperature regulation.
• Alleviation of vaginal dryness, itching, and discomfort, supporting sexual health.
• Improvement of mood swings, irritability, and sleep disturbances commonly experienced during menopause.
• Support for bone mineral density to help prevent osteoporosis associated with low estrogen levels.
• Mitigation of general fatigue and decreased energy levels that often accompany hormonal transition.

Goldar, like other tibolone preparations, may cause a range of side effects that vary in frequency and severity.

Common

• Mild nausea, abdominal discomfort, or indigestion.
• Transient headache or dizziness.
• Breast tenderness or mild swelling.
• Weight gain, fluid retention, or mild edema.
• Mood changes such as irritability or mild depression.

Serious

• Development of blood clots such as deep‑vein thrombosis or pulmonary embolism.
• Significant liver enzyme elevation indicating hepatic dysfunction.
• Potential increase in hormone‑dependent tumor growth, including breast or endometrial cancer.
• Severe allergic reaction with rash, itching, or swelling of the face.

When prescribing Goldar, clinicians consider several precautions to ensure safe use in women undergoing hormone replacement therapy.

• History of thromboembolic disorders such as deep‑vein thrombosis or stroke.
• Active or past breast, uterine, or ovarian cancer.
• Uncontrolled hypertension or cardiovascular disease.
• Severe liver disease or abnormal liver function tests.
• Pregnancy, lactation, or plans to become pregnant.
• Smoking, especially in women over 35 years of age.
• Known hypersensitivity to tibolone or any component of the formulation.

Goldar may interact with other medicines, affecting its efficacy or safety profile; certain combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce tibolone levels.
• Combination with anticoagulants (e.g., warfarin) that could increase clotting risk.

Use with caution

• Co‑administration with other hormonal agents such as estrogen or progestin may amplify hormonal effects.
• Use together with lipid‑lowering drugs (e.g., statins) as tibolone can affect lipid metabolism.
• Concurrent use with antidepressants, particularly SSRIs, may alter the management of mood‑related side effects.